India's First Dengue Vaccine Is Here - But Can the Poor Actually Finish Both Doses?

One Dose Is Not Half Protection

• Sometimes It's Worse Than None Picture a migrant construction worker who gets his first Qdenga shot at a public health camp in June, then moves for work before the second dose window in September arrives. He isn't half-protected. Depending on which dengue serotype finds him next, he may be barely protected at all - and he has no way of knowing that.

THE MANUFACTURER'S CASE, TAKEN SERIOUSLY

Building a vaccine against four serotypes at once is genuinely harder than building one against a single virus. Antibody-dependent enhancement means a poorly designed shot can make a second infection worse, as Dengvaxia's 2017 Philippines crisis proved. Takeda's caution and its price, reflect real R&D cost that a single-price global rollout likely couldn't recover. Tiered pricing is how global health access usually works

• it lets wealthier markets subsidize supply to poorer ones over time, rather than nobody getting the vaccine at all.

THE COST THAT PRICING TIERS DON'T SOLVE

WHO ACTUALLY FACES THIS RISK

It isn't a random slice of the population. It's people in dense slums with poor drainage - Aedes breeds in exactly the standing water those settlements can't drain - who are also least able to absorb Takeda's price and migrant workers whose mobility makes a fixed three-month return appointment the least reliable part of their week.

THE RESOLUTION

The easy answer would be to treat this as a rollout success with a pricing footnote to fix later. It isn't that. Vaccinating people into a partially-protected, DENV-3-exposed gap and calling it public health progress is a real harm, not a delay. The government should negotiate a lower tiered price specifically for below-poverty-line and migrant-registered populations and pair every first dose with a portable, transferable second-dose voucher usable at any public facility nationwide

• accepting the administrative cost of building that system as the real price of not leaving dose-one recipients worse off than if the vaccine had never reached them.